Key terms

About MRVI

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MRVI news

Yesterday 9:00am ET Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI) Apr 08 9:46pm ET RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI) Mar 18 9:10am ET Applied DNA Sciences enters manufacturing agreement with Alphazyme Mar 11 9:50pm ET Analysts Offer Insights on Healthcare Companies: Maravai Lifesciences Holdings (MRVI) and R1 RCM (RCM) Feb 26 9:41am ET Maravai LifeSciences trading resumes Feb 26 9:36am ET Maravai LifeSciences trading halted, volatility trading pause Feb 25 11:35pm ET Buy Rating Affirmed for Maravai Lifesciences Amid Strong Financial Performance and Growth Outlook Feb 23 10:29am ET Maravai LifeSciences trading resumes Feb 23 10:24am ET Maravai LifeSciences trading halted, volatility trading pause Feb 23 7:33am ET Stifel Nicolaus Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI) Feb 23 7:21am ET Maravai Lifesciences price target lowered to $10 from $11 at Stifel Feb 23 7:20am ET RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI) Feb 23 6:28am ET Maravai Lifesciences price target raised to $9 from $8 at BofA Feb 23 5:20am ET Maravai Lifesciences Holdings: Poised for Growth with Strong Q4 Performance and Promising FY2024 Outlook Feb 22 4:14pm ET Maravai Lifesciences reports Q4 adjusted EPS 1c, consensus (1c) Jan 26 8:47pm ET RBC Capital Reaffirms Their Buy Rating on Maravai Lifesciences Holdings (MRVI)

No recent press releases are available for MRVI

MRVI Financials

1-year income & revenue

Key terms

MRVI Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MRVI Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms